XBiotech
XBIT
53 hedge funds and large institutions have $18.6M invested in XBiotech in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 7 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
6% more funds holding
Funds holding: 50 → 53 (+3)
0.45% less ownership
Funds ownership: 15.93% → 15.47% (-0.45%)
50% less capital invested
Capital invested by funds: $37.5M → $18.6M (-$18.9M)
94% less call options, than puts
Call options by funds: $6K | Put options by funds: $96K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$301K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$219K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$207K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$190K |
| 5 |
VF
Virtu Financial
New York
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$1.96M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$183K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$155K |
| 4 |
Millennium Management
New York
|
-$119K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$94K |
XBIT Hedge Fund Activity: Q4 2024 in Review
53 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2024, worth a combined $18.6M — down 50% from $37.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XBIT positions and 7 closed out — a net gain of 3 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $301K. The largest seller was UBS AM, exiting entirely with an estimated $1.96M sold.
- 53 institutional investors held XBiotech (XBIT) as of Q4 2024, up from 50 in Q3 2024.
- Funds reported $18.6M of XBiotech stock for Q4 2024, down 50% quarter-over-quarter.
- 10 funds opened new XBiotech positions in Q4 2024 and 7 closed out, a net change of +3 holders.
- The largest XBiotech buyer in Q4 2024 was BlackRock, an estimated $301K added.
- The largest XBiotech seller in Q4 2024 was UBS AM, an estimated $1.96M sold.
Based on aggregated 13F filings for Q4 2024.